MedTrace Logo

Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma

NCT04756648 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-09-29

No results posted yet for this study

Summary

A Phase I Clinical Study ofCT0180 cells in Patients with Advanced Hepatocellular Carcinoma

Conditions

Interventions

DRUG

CT0180 Cells

Five dose levels were tentatively determined.

Sponsors & Collaborators

  • CARsgen Therapeutics Co., Ltd.

    collaborator INDUSTRY

  • Zhejiang University

    lead OTHER

Principal Investigators

  • Tingbo Liang · The First Affiliated Hospital, Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-10
Primary Completion
2023-03-31
Completion
2026-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04756648 on ClinicalTrials.gov